Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder.

Abstract

Moclobemide is a reversible selective inhibitor of monoamine oxidase A. It has proven efficacy in a wide range of depressive disorders, including agitated anxious depression. In an international, multicentre, double-blind parallel-group study, the tolerability and efficacy of moclobemide were compared with that of the selective serotonin reuptake inhibitor fluoxetine. The target dose of moclobemide was 450 mg/day in the dose range of 300-600 mg/day, while the target dose for fluoxetine was 20 mg/day in the dose range of 10-30 mg/day. There were two consecutive studies. The first was an 8-week short-term study of acute adverse events, tolerability and efficacy. The efficacy data showed no significant difference between moclobemide and fluoxetine. Evaluation of the tolerability in a long-term study of up to 1 year is still in progress. A review of the moclobemide safety database for panic disorder with 624 patients showed a marginal increase in events with moclobemide compared with placebo for insomnia (11.2%), dizziness (4.5%) and dry mouth (3.7%), with rates for headaches and nausea lower for moclobemide than placebo. These data suggest moclobemide is a well tolerated and effective treatment for panic disorder.

• Authors: J W Tiller, C Bouwer, K Behnke
• Journal: International clinical psychopharmacology (Int Clin Psychopharmacol) Vol. 12 Suppl 6 Pg. S27-30 (Oct 1997) ISSN: 0268-1315 [Print] England
• PMID: 9466172 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Benzamides
• Monoamine Oxidase Inhibitors
• Serotonin Uptake Inhibitors
• Fluoxetine
• Moclobemide

Topics

• Adult
• Anxiety (drug therapy, psychology)
• Benzamides (adverse effects, therapeutic use)
• Blood Pressure (drug effects)
• Female
• Fluoxetine (adverse effects, therapeutic use)
• Humans
• Male
• Moclobemide
• Monoamine Oxidase Inhibitors (adverse effects, therapeutic use)
• Panic Disorder (drug therapy, psychology)
• Psychiatric Status Rating Scales
• Selective Serotonin Reuptake Inhibitors (adverse effects, therapeutic use)
• Time Factors